DOAC Dosing for 16 kg Pediatric Proximal Thromboembolism
For a 16 kg child with proximal thromboembolism, administer rivaroxaban 5 mg twice daily (total daily dose 10 mg) using oral suspension. 1
Weight-Based Rivaroxaban Dosing
According to the 2025 ASH/ISTH pediatric VTE guidelines, a 16 kg child falls into the 12-29.9 kg weight category, which requires:
- Dose: 5 mg twice daily
- Formulation: Oral suspension only (tablets not appropriate at this weight)
- Total daily dose: 10 mg 1
This represents the most current evidence-based dosing recommendation from the highest quality guideline available.
Key Practical Considerations
Formulation Requirements
- At 16 kg, only oral suspension should be used - tablets are reserved for children ≥30 kg 1
- Oral suspension and tablets cannot be substituted on a milligram-to-milligram basis
Monitoring
- Rivaroxaban does not require routine laboratory monitoring 1
- No need for anti-Xa level checks in standard therapeutic use
Common Pitfalls to Avoid
- Do not use tablets at this weight - the dosing table specifically restricts this weight range to oral suspension only
- Do not dose once daily - children in the 12-29.9 kg range require twice-daily dosing, unlike heavier children who transition to once-daily regimens
- Do not bridge with heparin - DOACs can be started directly without initial parenteral anticoagulation in most cases 2
Safety Profile
Real-world pediatric data demonstrates acceptable safety with DOACs:
- No major bleeding events in recent Australian cohort of 74 treatment episodes 2
- Treatment failure rate approximately 5% 2
- Clinically relevant non-major bleeding occurs in ~4% of cases 2
Bleeding Management Protocol
If major bleeding occurs on rivaroxaban:
- Immediately hold the medication
- Consider 3- or 4-factor prothrombin complex concentrate (PCC) 1
- Activated charcoal if last dose was within 2 hours 1
- Andexanet alfa is an option for older adolescents but lacks pediatric data 1
Periprocedural Management
If procedures are needed while on therapy:
- Low-risk bleeding procedures: Pause 24 hours before
- High-risk bleeding procedures: Pause 48 hours before 1
Note that these recommendations are extrapolated from adult data and may not fully account for the shorter half-life in younger patients 1.